LisaTaliadoros

Partner-in-Charge Melbourne

Perth + 61.3.9101.6821 Sydney + 61.2.8272.0529

Contact

Partager

Head of the Intellectual Property Practice in Australia, Lisa Taliadoros has nearly 20 years of experience in high-value IP disputes, including in relation to patents, copyrights, and trademarks.

A focus of Lisa's practice is complex, multijurisdictional patent litigation in the Federal Court of Australia. She has acted across a range of industries, including pharmaceuticals, life sciences, biotechnology, mining, and building and construction. Lisa has acted in the High Court of Australia in two recent landmark decisions concerning the scope of patent protection for Myriad's BRCA1 (breast cancer) patents and Sanofi's leflunomide patent for the treatment of skin disorders and arthritic conditions. In addition, she has acted in the Federal Court of Australia for other large multinational pharmaceutical companies in matters relating to patents for new compounds, biologics, biosimilars, drug formulations, drug delivery devices, dental technology, and methods of treatment. She also has acted in matters concerning patents relating to mining tools and technologies (including deep water drilling apparatus) and building systems.

Lisa is a member of the Intellectual Property Law Subcommittee of the Law Council of Australia.

Prior to obtaining her law degree, Lisa was a scientist at two of Australia's preeminent research organizations, the CSIRO and the Centenary Institute of Cell Biology and Cancer Medicine. Her research projects involved the development of vaccines for avian infectious bronchitis virus and investigating the role of lymphotoxin alpha in the pathogenesis of autoimmune disorders.

Lisa is Partner-in-Charge of the Melbourne Office and serves as Jones Day's diversity partner for Australia.

Expérience

  • Sanofi challenges Amgen's patent applications for anti-PCSK9 antibodies before Australian Patent OfficeJones Day is acting in an opposition proceeding for Sanofi and Regeneron in relation to their challenge to a portfolio of applications held by Amgen Inc. that claim anti-PCSK9 antibodies and their use in the treatment of hypercholesterolemia.
  • Myriad acts in High Court's first consideration of genetic material patentsJones Day acted for Myriad Genetics, Inc. in a landmark Australian case before the High Court of Australia.
  • ToolGen defends revolutionary CRISPR technology patentJones Day is acting for ToolGen, Inc. in relation to a challenge to its patent rights concerning CRISPR, a technology that has revolutionized the field of molecular biology including gene editing in the medical, biotechnology, and agricultural and farming industries.
  • Bradken successfully defends patent infringement case brought by CQMS concerning mining equipmentJones Day acted for Bradken Limited in its successful defense against claims made by CQMS Pty Ltd that Bradken infringed patents concerning ground engaging tools.
  • Idenix asserts patent infringement against Gilead in Australia related to Sovaldi® and Harvoni®Jones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in the Federal Court of Australia over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
    •

    July 2023 Commentary

    Amendments to Australia's Modern Slavery Act Anticipated Following Statutory Review

    July 2021 Newsletters

    Australian Court Holds That Use of a Corporate Logo for Purposes of Engaging in a Public Campaign Amounts to Mostly Fair Dealing

    July 2021 Newsletters

    The Climate Report | Third Quarter 2021

    April 2020 White Paper

    Quick Reference Guide: Compulsory Patent Licensing During COVID-19 Crisis

    September 2019 Alert

    Australia Repeals IP Exemptions From Antitrust Rules

    July 2018 Commentary

    Federal Court of Australia Grants First Interlocutory Injunction Against Biosimilar

    June 2018 Commentary

    High Court of Australia Settles Principles for Preliminary Discovery

    April 2018 Commentary

    IP Rights Reform Is Price to Pay for Revamped Trans-Pacific Partnership Agreement

    Avant d’envoyer cet e-mail, veuillez prendre note de ce qui suit :

    Les informations contenues sur le site www.jonesday.com sont destinées à un usage général et ne constituent pas des conseils juridiques. L’envoi et la réception de cet e-mail n’ont pas pour effet de créer une relation avocat-client. Aucun envoi de votre part à un membre du Cabinet ne sera traité comme confidentiel ou protégé à moins que nous n’ayons donné notre accord pour vous représenter. En envoyant cet e-mail, vous confirmez avoir lu et compris la présente notification.